Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Response from IR re: meeting and patent expiration dates

Investment without some sort of future Business Plan. Shareholders want to resell their 400M shares, but who, and how much will they pay/buy with this type of eroding time limitation on future license producing opportunities; even with the very short "Look Back" recovery period.

This limit of recovery coupled with our history of failed leadership and UNfriendly actions towards the company's Shareholders, is a huge problem to our attractiveness for new investors. As we have also seen, the legal system provides plenty of methods to delay, and we have yet to have a full fledged "Win" that underwent an appeal.

Patents are wasting assets, the problem is that PTSC has no official Business Plan to deal with this. Investors think (invest) forward, and those patent expirations are what they see in PTSC's future. As each day passes, present investors are becoming more and more captive to riding this out to the very end, and hoping the dividend payouts will produce an acceptable ROI.

5,530,890- June 25, 2013
5,604,915- Feb. 18, 2014
5,659,703- Aug. 19, 2014
5,784,584- July 21, 2015
5,809,336- Sept. 15, 2015

If you think about the PDS operation, how how much of the MMP Gross license revenue will reach PTSC's top line, 30-35% ? Of that, how much will reach PTSC's bottom line, 70-80% ? Of that, if there is a continuous dividend declaration, how much of the bottom line would likely be distributed out, 75% ? What does that leave for per share payout to Shareholders ?

"Crickets" continue to be the sound coming from our Boardroom.

Do the calculations yourself ...

Share
New Message
Please login to post a reply